Technology
Health
Biotechnology

Adverum Biotechnologies

$5.41
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.10 (-1.81%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ADVM and other stocks, options, ETFs, and crypto commission-free!

About

Adverum Biotechnologies, Inc. Common Stock, also called Adverum Biotechnologies, is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. Read More It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

Employees
82
Headquarters
Menlo Park, California
Founded
2006
Market Cap
346.94M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
586.60K
High Today
$5.54
Low Today
$5.35
Open Price
$5.47
Volume
139.52K
52 Week High
$7.73
52 Week Low
$2.62

Collections

Technology
Health
Biotechnology
Medical
Gene Therapies
2016 IPO
US
North America

News

MarketBeatMar 14

Stock Price, News, & Analysis for Adverum Biotechnologies

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates that target serious rare and ocular diseases. It leverages its adeno-associated virus (AAV)-based directed evolution platform to develop products. The company's pipeline of product candidates include ADVM-043 to treat alpha-1 antitrypsin deficiency, which is in Phase I/II clinical trial; and ADVM-053 for hereditary angioedema disease, which is in preclinical stage; as well as ADVM-022 ...

27
Seeking AlphaMar 12

Adverum Biotechnologies (ADVM) Investor Presentation - Slideshow

The following slide deck was published by Adverum Biotechnologies, Inc. in conjunction with this event. 1 21 Click to enlarge Notes:...

86
Seeking AlphaFeb 28

Adverum Biotechnologies (ADVM) Presents At SVB Leerink 8th Global Healthcare Conference - Slideshow

The following slide deck was published by Adverum Biotechnologies, Inc. in conjunction with this event. 1 21 Click to enlarge Notes:...

147

Earnings

-$0.37
-$0.33
-$0.29
-$0.25
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.